1. Home
  2. Analysis
  3. Superinvestors
Superinvestors

Paulson’s Q3 13F: Madrigal Surges to 26%, PVH Bought as Alphabet Exits

John Paulson lifted his $2.9B book in Q3 2026, boosting Madrigal to 26%, buying PVH, and dumping Alphabet. Inside Paulson & Co.’s nine-stock filing.

BMInsider desk · · 3 min read

Billionaire investor John Paulson expanded his concentrated U.S. equity portfolio by 11.5% to $2.9 billion in the third quarter of 2026, filing his latest Form 13F with the SEC on November 16. For retail investors tracking smart-money conviction, Paulson & Co.’s nine-position book reveals an aggressive bet on commercial biotech growth, a tactical entry into discounted apparel, and an exit from mega-cap tech.

Form 13F filings disclose long U.S. equity holdings and options as of September 30, reaching the public with an approximate 45-day regulatory lag.

What happened

Paulson & Co. ended the third quarter with $2.9 billion in reported equity holdings across just nine positions, up from $2.6 billion in Q2. Rather than broadening his exposure, Paulson intensified his top winning bet, initiated two new stakes, and exited Alphabet.

The fund’s top holding, Madrigal Pharmaceuticals [MDGL], expanded to 25.77% of the portfolio as Paulson bought 11% more shares. Madrigal’s Rezdiffra—the first FDA-approved oral treatment for metabolic dysfunction-associated steatohepatitis (MASH)—drove the biotech to its first-ever profitable quarter in Q3 2026, generating $431.3 million in net revenue. While early November was clouded by a whistleblower lawsuit from a former executive alleging suppressed liver data, the stock traded around $427 in mid-November.

Paulson also initiated a 1.58% position in PVH Corporation [PVH], acquiring 620,820 shares worth roughly $46 million. The owner of Calvin Klein and Tommy Hilfiger traded near $93.33 in mid-November at an undemanding 7.5x to 8.5x forward earnings, beaten down by European wholesale weakness and non-cash write-downs.

A second new position emerged in Warner Bros. Discovery [WBD] with a nominal 0.03% allocation (25,000 shares valued at $774,000). While peers like Dan Loeb dumped WBD, Paulson took a modest toe-hold.

Paulson also added 5% to small-cap marketing software firm Thryv Holdings [THRY] (0.48%) and completely liquidated his remaining 0.07% stake in Alphabet [GOOGL]. Major core stakes Perpetua Resources [PPTA] (23.92%), Acadian Asset Management [AAMI] (18.37%), Bausch Health [BHC] (14.64%), International Tower Hill Mines [THM] (9.14%), and NovaGold Resources [NG] (6.07%) remained unchanged.

Why it matters

Paulson’s filing offers a clear contrast to standard diversification. His top four positions—MDGL, PPTA, AAMI, and BHC—make up over 82% of the entire portfolio, and his top six exceed 97%. Rather than indexing, Paulson runs an unapologetic, high-conviction event-driven strategy.

In Madrigal, Paulson is backing a commercial inflection point. Rezdiffra’s rapid adoption provides cash flows that de-risk the valuation, even amid legal noise. In Perpetua Resources, he controls a critical domestic asset: Idaho’s Stibnite project holds the only major U.S. reserve of antimony, an essential defense mineral backed by government export loans alongside rich gold deposits.

The new bet on PVH reflects opportunistic value hunting. Instead of paying steep multiples for artificial intelligence hype, Paulson targeted an apparel titan trading below 0.5 times sales, supported by multi-year supply chain optimizations targeting $150 million in annual cost savings by 2028. Selling Alphabet confirms a deliberate pivot away from mega-cap tech toward tangible, idiosyncratic corporate turnarounds.

What to watch next

  • PVH Q3 Earnings (December 2, 2026): Consensus calls for EPS of $2.63; watch direct-to-consumer margin stability and European wholesale trends.
  • Madrigal Whistleblower Defense: Legal developments in Dr. Michael Charlton’s Sarbanes-Oxley suit and Rezdiffra label expansion into cirrhosis.
  • Stibnite Financing & Approvals (PPTA): Progress on U.S. Export-Import Bank loan packaging and final mining permits in Idaho.
  • Bausch Health Separation (BHC): Refinancing updates and the pending completion of the Bausch + Lomb spin-off.

Stocks in this analysis

AI stock analysis

Free on aktienanalyse.ai: score profile, ratios versus the industry and business model. Plus, if you want it, the full analysis with fair value and bull, base and bear case. Prices and ratios as of Nov 16, 2026.

Sources (3)
  1. SEC Form 13F-HR - Paulson & Co. Inc.
  2. Madrigal Pharmaceuticals Reports Q3 2026 Financial Results
  3. PVH Corp. SEC Filings & Investor Relations

This analysis is for information only and is not investment advice. Prices and figures as of publication.

AI stock analysis

Any stock analysed in minutes

Business model, balance sheet, valuation and scenarios: aktienanalyse.ai builds a thorough analysis of any stock in minutes, with a fair value and bull, base and bear cases.

Analyse a stock → Stock profiles